Trastuzumab deruxtecan as first-line chemotherapy in Hormone-Receptor positive, HER2-low, metastatic breast cancer.
DESTINY-Breast06 : why I hope there won't be a standing ovation at ASCO-2024.
DESTINY-Breast06 : why I hope there won't be…
DESTINY-Breast06 : why I hope there won't be a standing ovation at ASCO-2024.
Trastuzumab deruxtecan as first-line chemotherapy in Hormone-Receptor positive, HER2-low, metastatic breast cancer.